Drug Type Biosimilar, Monoclonal antibody |
Synonyms rituximab biosimilar(Zenotech Laboratories Ltd.) |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date IN (01 Feb 2013), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Hodgkin Lymphoma | IN | 01 Feb 2013 |
Phase 3 | 398 | mdkeyutxqp(ewwskzgqsw) = The incidence of malignancy was low in both groups foiihkzfda (zgccwsocig ) View more | Positive | 14 May 2020 | |||
Not Applicable | 54 | xdepvwpuvw(xryfhirmcq) = Grade 3&4 AEs were anemia (n=6; 11%) tcwvmtiyvt (fgfejcghuf ) View more | - | 14 May 2020 | |||
Not Applicable | 70 | odnotsppnr(yaxdivnjku) = tnmuqavnux cbzsnwqlqg (trtywjpaxw ) | - | 14 Jun 2019 | |||
Not Applicable | - | vesjkxvgll(krudidxvqr) = vwzckqlyqj kfshemajwk (egaxatxouz ) | - | 16 May 2019 |